Drug intelligence / Profile preview

ganitumab + metformin

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of ganitumab, a monoclonal antibody targeting the type I insulin-like growth factor receptor (IGF-1R), and metformin, an oral antidiabetic medication. This combination was investigated primarily in breast cancer clinical trials, with metformin added to counteract ganitumab-induced hyperglycemia. The combination has shown modest activity in clinical trials but has not advanced to phase III studies.

Targets

ND1 (Mitochondrial electron transport chain complex I)AMPK (Adenosine monophosphate–activated protein kinase)IGF-1R (Insulin-like growth factor 1 receptor)OCT (Organic cation transporter family)

Beyond the preview

Go deeper on ganitumab + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganitumab + metformin.

Explore the full profile